Specify a stock or a cryptocurrency in the search bar to get a summary
Innoviva Inc
INVAInnoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. Address: 1350 Old Bayshore Highway, Burlingame, CA, United States, 94010
Analytics
WallStreet Target Price
15 USDP/E ratio
18.6533Dividend Yield
8.87 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures INVA
Dividend Analytics INVA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History INVA
Stock Valuation INVA
Financials INVA
Results | 2019 | Dynamics |